Literature DB >> 22743615

LTBP-2 confers pleiotropic suppression and promotes dormancy in a growth factor permissive microenvironment in nasopharyngeal carcinoma.

Han Chen1, Josephine Mun Yee Ko, Victor Chun Lam Wong, Marko Hyytiainen, Jorma Keski-Oja, Daniel Chua, John M Nicholls, Florence Man Fung Cheung, Anne Wing Mui Lee, Dora Lai-Wan Kwong, Pui Man Chiu, Eugene R Zabarovsky, Sai Wah Tsao, Qian Tao, Rebecca Kan, Stephen Ho Kin Chan, Eric J Stanbridge, Maria Li Lung.   

Abstract

This study identified LTBP-2 as a pleiotropic tumor suppressor in nasopharyngeal carcinoma, which safeguards against critical malignant behaviors of tumor cells. LTBP-2 expression was significantly decreased or lost in up to 100% of NPC cell lines (7/7) and 80% of biopsies (24/30). Promoter hypermethylation was found to be involved in LTBP-2 silencing. Using a tetracycline-regulated inducible expression system, we unveiled functional roles of LTBP-2 in suppressing colony formation, anchorage-independent growth, cell migration, angiogenesis, VEGF secretion, and tumorigenicity. Three-dimensional culture studies suggested the involvement of LTBP-2 in maintenance of tumor cell dormancy in a growth factor favorable microenvironment.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22743615     DOI: 10.1016/j.canlet.2012.06.005

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

1.  New insights into tumor dormancy: Targeting DNA repair pathways.

Authors:  Elizabeth B Evans; Shiaw-Yih Lin
Journal:  World J Clin Oncol       Date:  2015-10-10

2.  Latent transforming growth factor β-binding protein 4 is downregulated in esophageal cancer via promoter methylation.

Authors:  Insa Bultmann; Anne Conradi; Celine Kretschmer; Anja Sterner-Kock
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

3.  NF-κB p65 Subunit Is Modulated by Latent Transforming Growth Factor-β Binding Protein 2 (LTBP2) in Nasopharyngeal Carcinoma HONE1 and HK1 Cells.

Authors:  Rebecca Kan; Wai Ho Shuen; Hong Lok Lung; Arthur Kwok Leung Cheung; Wei Dai; Dora Lai-Wan Kwong; Wai Tong Ng; Anne Wing Mui Lee; Chun Chung Yau; Roger Kai Cheong Ngan; Stewart Yuk Tung; Maria Li Lung
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

Review 4.  EMT, CTCs and CSCs in tumor relapse and drug-resistance.

Authors:  Abhisek Mitra; Lopa Mishra; Shulin Li
Journal:  Oncotarget       Date:  2015-05-10

Review 5.  The interplay of host genetic factors and Epstein-Barr virus in the development of nasopharyngeal carcinoma.

Authors:  Maria Li Lung; Arthur Kwok Leung Cheung; Josephine Mun Yee Ko; Hong Lok Lung; Yue Cheng; Wei Dai
Journal:  Chin J Cancer       Date:  2014-11

6.  Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention.

Authors:  Sih-Han Wang; Shiaw-Yih Lin
Journal:  Exp Hematol Oncol       Date:  2013-10-16

Review 7.  Cancer cell dormancy: mechanisms and implications of cancer recurrence and metastasis.

Authors:  Xiao-Lei Gao; Mei Zhang; Ya-Ling Tang; Xin-Hua Liang
Journal:  Onco Targets Ther       Date:  2017-10-27       Impact factor: 4.147

8.  Latent Transforming Growth Factor β Binding Protein 2 (LTBP2) as a Novel Biomarker for the Diagnosis and Prognosis of Pancreatic Carcinoma.

Authors:  Cheng Wang; Gang Wang; Lu Zhang; Jingen Pan; Yajun Wei
Journal:  Med Sci Monit       Date:  2017-07-03

9.  Integrated mRNA and microRNA transcriptome sequencing characterizes sequence variants and mRNA-microRNA regulatory network in nasopharyngeal carcinoma model systems.

Authors:  Carol Ying-Ying Szeto; Chi Ho Lin; Siu Chung Choi; Timothy T C Yip; Roger Kai-Cheong Ngan; George Sai-Wah Tsao; Maria Li Lung
Journal:  FEBS Open Bio       Date:  2014-01-13       Impact factor: 2.693

Review 10.  Factors involved in cancer metastasis: a better understanding to "seed and soil" hypothesis.

Authors:  Qiang Liu; Hongfei Zhang; Xiaoli Jiang; Caiyun Qian; Zhuoqi Liu; Daya Luo
Journal:  Mol Cancer       Date:  2017-12-02       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.